NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

TSX · Biotechnology · CAD

Fennec Pharmaceuticals Inc. (FRX.TO) Stock Analysis

Fennec Pharmaceuticals Inc. (FRX.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.

Last Updated: October 20, 2026

FRX.TO

CA$14.76

+CA$0.86 (+6.19%)

Oct 20, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FRX.TO with… →

FRX.TO Key Statistics

As of Oct 20, 2026
Trading
Open
CA$14.71
Previous Close
CA$13.90
Day's Range
14.71–14.77
52-Week Range
7.59–17.64
Volume
420.00
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.23
Valuation
Market Cap
CA$517.59M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
11.20
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
8.74
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.17
Financials (FY)
Revenue (FY)
CA$44.64M−6.09%
Net Income (FY)
−CA$9.74M
Profit marginThe share of revenue left as profit after all costs and taxes.
−5.49%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
35.07M
1-Year Return
+27.35%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
448.00

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 20, 2026, FRX.TO closed at CA$14.76, +27.35% over 1 year.

Fennec Pharmaceuticals Inc. (FRX.TO) has a market capitalization of CA$517.59M.

In fiscal 2025, FRX.TO reported revenue of CA$44.64M.

FRX.TO Stock Return by Calendar Year

Fennec Pharmaceuticals Inc. (FRX.TO) 10-year return: what CA$10,000 became

1 year
CA$10,000 CA$12,735
+27.35%
5 years
CA$10,000 CA$13,418
+34.18%
10 years
CA$10,000 CA$57,882
+478.82%

If you had invested CA$10,000 in Fennec Pharmaceuticals Inc. (FRX.TO) 10 years ago, at the close on October 20, 2016, it would have been worth CA$57,882 at the close on October 20, 2026: +478.82% in total, +19.19% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+39.25%
2025+19.50%
2024−41.49%
2023+15.81%
2022+133.75%
2021−38.39%
2020+7.57%
2019−1.17%
2018−31.55%
2017+378.54%
2016 (partial year)−6.79%

As of October 20, 2026.

FRX.TO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025CA$44.64M−CA$9.74M−21.8%
2024CA$47.54M−CA$436.00K−0.9%
2023CA$21.25M−CA$16.05M−75.5%
2022CA$1.54M−CA$23.71M−1,544.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$44.64MCA$40.88M−CA$6.35M−CA$9.74M−21.8%
2024CA$47.54MCA$44.35MCA$2.48M−CA$436.00K−0.9%
2023CA$21.25MCA$19.99M−CA$13.06M−CA$16.05M−75.5%
2022CA$1.54MCA$1.45M−CA$22.74M−CA$23.71M−1,544.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FRX.TO Valuation vs Biotechnology Median

Median of 608 stocks
MetricFRX.TOBiotechnology medianvs median
P/S ratio8.7413.3034% below
Profit margin−5.49%−38.31%32.8 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

The market values Fennec Pharmaceuticals Inc. (FRX.TO) at CA$517.59M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 35.

Over the past 52 weeks the price has ranged from CA$7.59 to CA$17.64. The most recent close on file for FRX.TO is CA$14.76, dated October 20, 2026. That is +CA$0.86 (+6.19%) against the previous close. The latest close sits 94.47% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to CA$44.64M. Against the prior fiscal year total of CA$47.54M, that is a change of −6.09%. The same year closed with a net loss of CA$9.74M. The reported profit margin is −5.49%. That is 32.8 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are −0.17.

Across the 4 fiscal years on file, revenue moves from CA$1.54M in 2022 to CA$44.64M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 11.2. The price-to-sales ratio is 8.74. On price-to-sales that is 34.28% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.23. Annualized volatility over the trailing 10 years is 66%. The trailing one-year total return is +27.35%. Across 10 years the annualized return works out at +19.19%.

Growth & Income

No dividend is on file for FRX.TO.

The strongest complete calendar year on file is 2017 at +378.54%; the weakest is 2024 at −41.49%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the total return is +39.25% year to date.

Peer Comparison

Fennec Pharmaceuticals Inc. (FRX.TO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Fennec Pharmaceuticals Inc. FRX.TO CA$517.59M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

Market caps are shown in each company's own trading currency, without conversion, and the peers are listed in order of these unconverted figures.

The Biotechnology industry average P/E ratio is 16.6x. Fennec Pharmaceuticals Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 20, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Visit website →